Core Insights - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1] - Neuphoria's lead drug candidate, BNC-210, is designed for the treatment of social anxiety disorder and post-traumatic stress disorder, offering rapid relief without common side effects [3] Company Overview - Neuphoria is advancing BNC-210, a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor [3] - The drug aims to restore neurotransmitter balance and is characterized as a well-tolerated, broad-spectrum anti-anxiety therapeutic [3] - The company has a strategic partnership with Merck & Co., Inc. for two drugs in early-stage clinical trials targeting cognitive deficits in Alzheimer's disease and other CNS conditions [3] Upcoming Events - The presentation by Spyros Papapetropoulos, M.D., Ph.D., will be available on demand starting September 5, 2025 [2] - The webcast can be accessed through the "Events" page in the investors section of Neuphoria's website [2]

Core Insights - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders, with a lead drug candidate BNC210 targeting social anxiety disorder and post-traumatic stress disorder [2][4] Company Overview - Neuphoria is advancing BNC210, an oral selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, designed for acute and chronic treatment of anxiety disorders [2] - The company has a strategic partnership with Merck & Co., Inc. for two drugs in early-stage clinical trials aimed at cognitive deficits in Alzheimer's disease and other CNS conditions [2] - Neuphoria's pipeline includes next-generation α7 nicotinic acetylcholine receptor programs and Kv3.1/3.2 preclinical programs, both in lead optimization development [2] Upcoming Events - Neuphoria will present a pharmacokinetic/pharmacodynamic analysis of the BNC210 Attune Phase 2b dataset at the ASCP 2025 Annual Meeting, scheduled for May 28, 2025 [4]

Core Insights - Neuphoria Therapeutics Inc. is making steady progress in its clinical pipeline, particularly with its lead program BNC210 for Social Anxiety Disorder and partnered asset MK-1167 for Alzheimer's disease [2][6] Clinical Programs - BNC210 is currently enrolling in the AFFIRM-1 Phase 3 study for Social Anxiety Disorder, with topline data expected in Q3 2025 [2][7] - MK-1167 is in a Phase 2 trial led by Merck for Alzheimer's disease, showing continued momentum [2][4] - A Phase 2b trial (SYMPHONY) for BNC210 in PTSD is being planned following a successful End-of-Phase 2 meeting with the FDA [7] Product Details - BNC210 is a first-of-its-kind oral therapy designed to treat social anxiety disorder and PTSD without sedation, cognitive impairment, or addiction potential [4][7] - The drug acts as a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, aiming to restore neurotransmitter balance [4] Financial Outlook - The company has a cash runway extending into Q3 2026, supporting ongoing clinical trials and development efforts [6]